| Company Name: | Achillion Pharmaceuticals, Incorporated | | Ticker Symbol: | ACHN | | | WWW Address: | www.achillion.com | | CEO: | Michael D. Kishbauch | | No. of Employees: | 54 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, focused on the discovery, development and commercialization of innovative treatments for infectious diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.92 |  0.02 | 1.05 | 2.87 | 1.94 | 1.99 | 1.92 | 14425 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 51.3 | 26.7 | -0.41 | -1.42 | 0.00 | 0.0 | 0.0 | 2.42 - 0.65 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.92 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 51.2 | mil |
| Latest Shares Outstanding | 26.7 | mil |
| Earnings pS (EPS) | -1.42 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | -4,333 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 26.5 | mil |
| Float as % of Shares Outstanding | 99.6 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | -384.30 | % |
| Research & Devlopment (R&D) as % of Revenue | -1,180.60 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | -0.1 | % |
| Return on Assets (ROA) | -160.6 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -386.8 | % |
| Current Ratio | 2.1 | |
| Leverage Ratio (Assets/Equity) | 2.4 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.53 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.31 | $ |
| Cash pS | 0.35 | $ |
| Book-Value pS | 0.27 | $ |
| Tangible Book-Value pS | 0.27 | $ |
| Cash Flow pS | -1.01 | $ |
| Free Cash Flow pS | -0.93 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 7.09 | |
| Price/Tangible Book Ratio | 7.09 | |
| Price/Cash Flow | -1.9 | |
| Price/Free Cash Flow | -2.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 100 | 434 | 2,751 |
| 4 Weeks | 2.10 | 1.47 | 1.85 | 3.8 | 103 | 331 | 6,628 |
| 13 Weeks | 2.24 | 1.38 | 1.80 | 6.7 | 100 | 327 | 20,901 |
| 26 Weeks | 2.42 | 1.10 | 1.29 | 48.8 | 121 | 274 | 34,767 |
| 52 Weeks | 2.42 | 0.65 | 1.00 | 92.0 | 141 | 311 | 78,174 |
| YTD | 2.42 | 0.70 | - | 182.4 | 234 | 280 | 62,893 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 1.96 | 1.89 | 1.80 | 1.70 | 1.66 | -0.41 | -0.41 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 3.27 |
| R&D | 0.00 | NA | -3.29 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -133.8 | -316.0 | -105.8 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.38 | 0.07 | 0.38 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 63.17 |
| Current Ratio | 3.0 |
| Quick Ratio (Acid Test) | 2.9 |
| Liquidity Ratio (Cash) | 2.90 |
| Receivables Turnover | -0.4 |
| Average Collection Period | -900 |
| Working Capital/Equity | 97.4 |
| Working Capital pS | 0.92 |
| Cash-Flow pS | -1.05 |
| Free Cash-Flow pS | -0.95 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -0.33 |
| Financial Leverage Ratio (Assets/Equity) | 1.5 |
| Debt Ratio | 35.1 |
| Total Debt/Equity (Gearing Ratio) | 0.25 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 5.4 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 4.02 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.93 |
| Tobin's Q Ratio | 1.33 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -1.07 |
| Enterprise Value (EV)/Free Cash Flow | -0.62 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 7.09 |
| Price/Book Ratio - LTM | 7.09 |
| Price/Cash Flow Ratio | -1.9 |
| Price/Free Cash Flow Ratio - LTM | -2.1 |
| Price/Sales Ratio | -31.25 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.46 |
| Tangible Book Value pS - LTM | 0.27 |
| Book Value pS - LTM | 0.27 |
| Capital Invested pS | 0.94 |
| Cash pS - LTM | 0.35 |
| Cash Flow pS - LTM | -1.01 |
| Free Cash Flow pS - LTM | -0.93 |
| Earnings pS (EPS) | -1.42 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 10,678.21 |
| Free Cash Flow Margin 5YEAR AVG | 1,645.15 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.01 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | -0.01 |
| Return on Capital Invested (ROCI) | -112.5 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 185.6 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -73.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -63.9 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.5 |
| Effective Tax Rate - 5YEAR AVRG. | 1.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 0 |
| Revenue per Employee | -4,333 |
| Net Income per Employee | -521,315 |
| Average Collection Period | 0 |
| Receivables Turnover | -0.4 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | -1,087.18 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | -0.01 |
| Fixed Assets Turnover | -0.12 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | -0.02 |
| Revenue per $ Plant | -0.13 |
| Revenue per $ Common Equity | -0.01 |
| Revenue per $ Capital Invested | -0.01 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | -2797.4 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 147.1 |
| Research & Devlopment (R&D) as % of Revenue | -9038.5 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | -9038.5 |
|
|  
|
| |
 |  |